HGEN - Humanigen inks manufacturing agreement for COVID-19 therapy lenzilumab

Humanigen (HGEN) and Chime Biologics have entered into a manufacturing services agreement to produce Humanigen's COVID-19 therapy lenzilumab's bulk drug substance and drug product.The agreement follows receipt of requisite regulatory authorizations in regions outside of the United States including Europe, the United Kingdom, India and Brazil.Under the terms of the agreement, Chime will use the state-of-the-art modular single use KuBio ((Cytiva)) biologics facility in China.Technical transfer work has already begun, and commercial product is planned to be available in 2022, the companies said.Humanigen had announced the publication of Phase 3 results of its lead asset lenzilumab in hospitalized COVID-19 patients, earlier this month.

For further details see:

Humanigen inks manufacturing agreement for COVID-19 therapy lenzilumab